Delivery of rapamycin to dendritic cells using degradable microparticles
- 1 February 2009
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 133 (3), 191-197
- https://doi.org/10.1016/j.jconrel.2008.10.011
Abstract
No abstract availableKeywords
Funding Information
- American Heart Association (0730081N)
- Transplantation Society
- National Institutes of Health (AI 60994, AI 67541, KL2 RR024154-02)
This publication has 41 references indexed in Scilit:
- A Microsphere-Based Vaccine Prevents and Reverses New-Onset Autoimmune DiabetesDiabetes, 2008
- What does the future hold for cell-based tolerogenic therapy?Nature Reviews Immunology, 2007
- Poly( d , l -Lactide-Coglycolide) Particles Containing Gentamicin: Pharmacokinetics and Pharmacodynamics in Brucella melitensis - Infected MiceAntimicrobial Agents and Chemotherapy, 2007
- PLGA nanoparticles for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral®Journal of Controlled Release, 2007
- Release of anti-restenosis drugs from poly(ethylene oxide)-poly(dl-lactic-co-glycolic acid) nanoparticlesJournal of Controlled Release, 2006
- Regulatory dendritic cell therapy in organ transplantationTransplant International, 2006
- Rapamycin-Treated, Alloantigen-Pulsed Host Dendritic Cells Induce Ag-Specific T Cell Regulation and Prolong Graft SurvivalAmerican Journal of Transplantation, 2005
- Dendritic cells: emerging pharmacological targets of immunosuppressive drugsNature Reviews Immunology, 2004
- Development of biodegradable microspheres and nanospheres for the controlled release of cyclosporin AInternational Journal of Pharmaceutics, 1993
- Macrophage phagocytosis of biodegradable microspheres composed of L‐lactic acid/glycolic acid homo‐ and copolymersJournal of Biomedical Materials Research, 1988